arrow
A

Afsaneh Barzi

pennsylvania medicine
H指数:29
被引数:6,673

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and Descriptive Safety Assessment of Programmed Cell Death Protein-(Ligand) 1 Inhibitors Plus Chemotherapy as First-Line Treatment for Gastric and Gastroesophageal Junction Cancer in Asian and Non-Asian Patients: A Meta-Analysis

亚洲和非亚洲患者中程序性细胞死亡蛋白-(配体)1抑制剂联合化疗作为胃癌和胃食管结合部癌一线治疗的疗效和安全性描述性评估:一项Meta分析

2026-01-010
OAAI
MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma: Trial in progress

MOUNTAINEER-02: tucatinib,曲妥珠单抗,ramucirumab和紫杉醇在先前治疗过的HER2胃或胃食管交界处腺癌中的2/3期研究: 正在进行的试验

2022-06-011
OA